Phase I data show B-cell depletion and mostly stable or improved disability scores, but the uncontrolled study remains small ...

Review examines how PAT, model-based control, reinforcement learning, and digital twins could maintain product quality from ...

John Wichelt discusses Kindeva’s Bridgeton facility, supporting injectable programs from clinical development through ...

The biggest bottleneck slowing progress in drug development is the competition for, and successful recruitment of, patients for participation in clinical trials, while also ensuring participants ...

The double-strand break-free approach increased functional GATA2 alleles and improved the engraftment of edited blood stem cells in mice ...

I have always loved science, but I originally expected to stay in academic research. I studied in the UK, completing my PhD at Durham University. During my PhD, the Stem Cell Network in Canada reached ...

Piers Ingram discusses the resurgence of immunology, engineering-led drug discovery, and why faster clinical execution will shape the next generation of medicines ...

Targeted lipid nanoparticles generate CAR NK cells in mice, showing activity against cancer and autoimmune liver disease ...

From analytical data management to automated structure verification, explore practical approaches to digitalization and AI in pharmaceutical R&D. Digitalization and AI initiatives depend on accessible ...

The year 2026 is anticipated to mark a significant transformation in life sciences, driven by the integration of Agentic AI into clinical research and biopharma. This shift aims to alleviate ...

We are all watching the rise of oral, small molecule GLP-1 receptor agonists with justified interest. The promising phase III results of Eli Lilly’s orforglipron has set the pace, and others are ...

China’s rise in biopharma is often framed as a competitive challenge to the West. For Lingshi Tan, Executive Chairman of Caidya, that framing misses the larger point: drug development itself is ...